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Introduction
Cells respond to external cues, such as growth factor stimulation, 
by adapting multiple aspects of their physiology. Downstream 
of cell surface receptors, signaling cascades impact upon protein 
synthesis, transcriptional programs, cytoskeleton dynamics, and 
adhesive properties of cells. To regulate these processes, signal 
transduction complexes associate with specific subcellular struc-
tures. Src family kinases (SFKs) form active signaling complexes 
on Golgi membranes (David-Pfeuty and Nouvian-Dooghe, 1990; 
Bard et al., 2002; Chiu et al., 2002). We have previously shown 
that SFKs are important for Golgi structural organization and 
regulation of COP-I–dependent traffic (Bard et al., 2003); how-
ever, the physiological role of Src at the Golgi remains unclear.
One role of the Golgi apparatus is the addition of glycan 
chains to proteins synthesized through successive addition of 
simple sugars by various glycosyltransferases. The two main 
types of glycosylation in the mammalian Golgi apparatus are 
N-glycosylation and O-GalNAc glycosylation (referred simply 
as O-glycosylation here). O-glycosylation initiation is thought 
to occur in the Golgi apparatus, although earlier reports had pro-
posed an ER location based on lectin staining (Pathak et al., 1988; 
Tooze et al., 1988; Perez-Vilar et al., 1991). O-glycosylation is 
initiated by a family of 20 enzymes called GalNac-Ts, which add 
N-acetyl-galactosamine (GalNAc) to Ser or Thr residues. Most 
O-glycosylation sites can be modified by multiple GalNac-T 
isoforms, but some isoforms also present site specificity and 
have different tissue expression patterns (Ten Hagen et al., 2003; 
Tarp and Clausen, 2008). Consistent with the importance of 
O-glycosylation for metazoans, GalNac-T1 and GalNac-T11 
are essential for Drosophila embryonic development (Schwientek 
et al., 2002; Zhang et al., 2008). Similarly, gene knockouts of 
GalNac-T1 and T3 in mouse result in severe phenotypes (Tenno 
et al., 2007; Ichikawa et al., 2009). O-glycosylation often occurs 
on several adjacent Ser or Thr, especially in mucin proteins 
and, by contrast with N-glycosylation, there is no consensus se-
quence identified for GalNAc addition. Several glycosyltrans-
ferases act after GalNac-Ts in a stepwise manner to form a 
complex array of O-linked glycan structures (Spiro, 2002; 
Freeze, 2006). O-glycosylation sites as well as O-glycan structures 
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of GalNac-T1 staining is apparent in punctate and diffuse cellular 
structures that stain positively for HPL (Fig. 2 B). Similar re-
sults were obtained upon PDGF stimulation (Fig. S1 F). Con-
sistent with the idea that GalNac-T1 is redistributed away from 
the Golgi apparatus, when using constant image acquisition param-
eters, the amount of GalNac-T1 at the Giantin-stained Golgi is 
significantly decreased after 4 h of EGF treatment (Fig. 2 C). 
Quantification of the ratio of Golgi/neighboring cytosol stain-
ing averaged over multiple cells confirmed that the amount of 
GalNac-T1 at the Golgi decreases progressively with longer 
EGF stimulation time (Fig. 2 D). Growth factor stimulation 
can alter cell physiology through changes in gene expression; 
however, addition of -Amanitin (a potent inhibitor of RNA 
polymerase II) does not prevent redistribution of HPL staining 
under EGF stimulation (Fig. S2), indicating that HPL staining 
redistribution is independent of transcription and more likely 
due to membrane trafficking events.
GalNac-T1 redistribution is dependent  
on Src activation
We next investigated whether Src activation was important for 
GalNac-T redistribution by treating HeLa cells with EGF and 
10 µM of Src kinase inhibitors (SU6656 or Src kinase inhibitor 1 
[SKI]; (Fig. 3 A). In cells without Src inhibitor treatment (DMSO 
only), the ratio of Golgi-specific HPL labeling dropped from 
fivefold to twofold after 4 h of EGF stimulation (Fig. 3, A and B). 
Strikingly, HPL redistribution was completely or partially blocked 
in cells treated with 10 µM SKI or SU6656, respectively, as 
apparent visually and after quantification (Fig. 3, A and B). 
Similar results were obtained upon inhibition of Src with 10 µM 
SKI after PDGF stimulation (Fig. 3 C). Src activity can also 
be up-regulated, for example in human breast cancer cells, by an   
increase in its expression levels (Ottenhoff-Kalff et al., 1992). 
As a model of such constitutive activation, we compared mouse 
fibroblast cell lines with different levels of Src activity: SYF, 
lacking Src/Yes/Fyn (ubiquitous SFKs), and SYFsrc, where Src 
has  been  reintroduced  into  SYF  cells  and  is  overexpressed 
threefold relative to normal fibroblasts (Klinghoffer et al., 1999). 
At low resolution, HPL staining has a perinuclear distribution in 
SYF cells, which is similar to most fibroblast cell lines tested. 
By contrast, a reticulated network is prevalent in SYFsrc cells 
(Fig. 3 D). At higher resolution, HPL staining colocalizes exclu-
sively with Mannosidase II (ManII)–stained Golgi membranes 
in SYF cells, whereas in SYFsrc cells, a reticulated network 
with punctate structures is also apparent (Fig. 3 E). In addition, 
significant additional redistribution of HPL staining from the 
Giantin-stained  Golgi  apparatus  was  observed  in  SYFsrc   
cells and not in SYF cells stimulated with EGF or PDGF for 
2 h (Fig. S3). Finally, to test whether Src can directly perturb 
GalNac-T localization, an active Src mutant tagged at its C termi-
nus with DsRed (SrcE-DsRed, containing the activating E378G 
mutation) and a GFP-tagged form of Mannosidase II (ManII-
GFP) were microinjected in human WI38 fibroblasts (cells that 
stain well for several GalNac-Ts). Soon after Src became detect-
able (3 h after microinjection), the perinuclear Golgi staining of 
GalNac-T1 was significantly decreased in microinjected cells, 
whereas the Golgi delineated by ManII-GFP remained normal, 
vary  dramatically between tissues (Hanisch, 2001), during in-
flammation (Crocker and Redelinghuys, 2008) and in cancer 
(Brockhausen, 2006). Regulation of O-glycosylation initiation 
is thought to depend mostly on the expression levels of GalNac-Ts. 
These variations are likely to carry a physiological importance 
as O-glycosylation can increase substantially the hydrophilicity 
and turgidity of cell surface glycoproteins and can affect the 
adhesive properties of cells. O-glycosylation also creates binding 
sites for glycoproteins, for example, selectins that mediate binding 
of leukocytes to endothelial cells (Ley and Kansas, 2004; Hang 
and Bertozzi, 2005).
Here, we investigated the effect of Src activation on local-
ization of various Golgi proteins and find that Src induces 
Golgi-to-ER retrograde trafficking of O-glycosylation initiation 
enzymes GalNac-Ts via a COP-I–dependent mechanism. This re-
location dramatically increases protein O-glycosylation initiation.
Results
Growth hormone stimulation redistributes 
GalNac-T1 from the Golgi apparatus
We have previously investigated the role of Src at the Golgi by 
comparing cell lines with different levels of Src expression (Bard 
et al., 2003). In normal cells, Src can be activated downstream 
of various growth factor receptors, such as EGF or PDGF re-
ceptors (Thomas and Brugge, 1997). To investigate whether 
such stimulation could affect Golgi physiology, we compared 
staining patterns of various Golgi markers in serum-starved HeLa 
cells with those further stimulated with EGF. The Helix poma-
tia lectin (HPL) marks Golgi membranes under usual growing 
conditions (10% FBS). Upon serum starvation, this staining 
pattern is not significantly affected (Fig. 1 A and Fig. S1, A and B). 
By contrast, upon EGF stimulation, HPL staining is significantly 
redistributed from its perinuclear localization while the Golgi 
marker Giantin is unaffected (Fig. 1 B). Similar results were 
obtained upon PDGF stimulation (Fig. S1 C). To quantify redistri-
bution of HPL, the ratio of staining between the Golgi and neigh-
boring cytoplasm was compared using a method outlined in 
Fig. 1 C and the amount of HPL staining at the Golgi was found 
to decrease progressively with longer EGF stimulation (Fig. 1 D). 
HPL binds various glycans but in particular to terminal -linked 
N-acetyl galactosamine residues (GalNAc) linked to Ser or Thr 
residues (Sanchez et al., 2006). This structure is also known as 
the Tn antigen. To verify that HPL staining indeed reflects mostly 
GalNAcs -linked to proteins in our various experimental condi-
tions, we compared anti-Tn antibody and HPL stainings and 
found that they colocalize at the Golgi before stimulation 
(Fig. 1 E) and are redistributed upon stimulation with EGF 
(Fig. 1 F). Identical results were obtained after stimulation with 
PDGF (Fig. S1, D and E).
GalNAc is added onto proteins by GalNac-Ts (Ten Hagen 
et al., 2003). Consequently, redistribution of anti-Tn and HPL 
staining by growth factor addition is likely due to relocation of 
GalNac-Ts normally localized at the Golgi apparatus (Röttger 
et al., 1998). Indeed, in unstimulated HeLa cells, GalNac-T1 and 
HPL colocalize exclusively at the Giantin-stained Golgi apparatus 
(Fig. 2 A), whereas after EGF treatment a significant amount 845 Src regulates protein O-glycosylation • Gill et al.
highlighting that Src can directly and rapidly induce GalNac-T 
redistribution from the Golgi apparatus (Fig. S4 A).
Several GalNac-Ts redistribute away from 
the Golgi apparatus
Although GalNac-T1 is a major and ubiquitous member of the 
family, GalNac-Ts form a family of 20 enzymes (Ten Hagen 
et al., 2003; Tarp and Clausen, 2008). To test whether other 
GalNac-Ts were redistributed from the Golgi upon Src activa-
tion, we used Src(E378G) microinjection in WI38 human fibro-
blasts as it induces a clear and strong redistribution of GalNac-T1 
without significant Golgi perturbation. Indeed, when Src activ-
ity is very high, such as after microinjection or transient trans-
fection of an activated kinase, some cell lines such as HeLa 
Figure 1.  Growth factor stimulation effect on O-glycosylation marker distribution. (A and B) Helix pomatia lectin (HPL) staining at the Golgi (Giantin) in 
unstimulated HeLa cells (A) is redistributed out of the Golgi after EGF treatment (100 ng/ml) for 4 h (B). (C) HPL staining at the Golgi or neighboring cyto-
plasm is measured to quantify the fold enrichment at the Golgi. (D) HPL enrichment at the Golgi progressively decreases with increased EGF stimulation. 
30 cells were quantified for each sample. Error bars show SEM. Statistical significance (p) measured by two-tailed paired t test. *, P < 0.001 relative to mean HPL 
staining in unstimulated cells (0 h). This is a representative example from three independent experiments. (E and F) Anti-Tn staining colocalizes with HPL at 
the Golgi in unstimulated HeLa cells (E) or away from the Golgi in punctate cytoplasmic structures after EGF treatment for 4 h (F). In all images nuclei were 
stained using Hoechst and colored blue. Bar, 10 µm.JCB • VOLUME 189 • NUMBER 5 • 2010   846
N-acetyl transferase 1 core 2 (C2GnT), an enzyme that func-
tions downstream of the GalNac-Ts (Fig. S5), suggesting that 
the O-glycosylation pathway is only targeted at the level of the 
initiation enzymes. A summary of all the Golgi markers tested 
and their results is presented in Table I.
Src activation redistributes GalNac-Ts 
from the Golgi to the ER
In both EGF-stimulated HeLa cells and activated Src SYFsrc 
fibroblasts, HPL appears to stain a reticulated network reminiscent 
of the ER and punctate structures distributed throughout the 
cytoplasm reminiscent of the ER-to-Golgi intermediate compart-
ment (ERGIC; Figs. 1 B and 3 E). Consistently, while in unstimu-
lated HeLa cells GalNac-T1 localizes in the perinuclear Golgi 
suffer a significant fragmentation of the whole Golgi appara-
tus. All GalNac-Ts tested (T1, T2, T3, T4, and T6) were redis-
tributed in this assay (Fig. S4, A–C; and unpublished data). By 
contrast, our initial screen on Src effect on Golgi markers 
had revealed that other Golgi enzymes, such as ManII and 
4-galatosyltransferase, are not redistributed after Src activation 
(Fig. S5). GalNac-Ts have been proposed to be present in the 
cis-Golgi cisternae (Roth et al., 1994), whereas the two previ-
ous enzymes are respectively medial and trans located. How-
ever, a known cis-Golgi enzyme, -1,2-mannosidase IC (ManIC), 
as well as the cis-Golgi marker GM130, were also not affected, 
indicating that cisternal localization alone cannot explain the 
specific redistribution of GalNac-Ts. Src expression also had no 
visible effect on the intracellular distribution of glucosaminyl 
Figure 2.  Src activation redistributes GalNac-T1 from the Golgi. (A and B) GalNac-T1 and HPL staining colocalizes only at the Golgi (Giantin) in unstimulated 
HeLa cells (A) but also in punctate cytoplasmic structures after EGF treatment (100 ng/ml) for 4 h (B). (C) The amount of GalNac-T1 staining colocalizing 
with Golgi membranes was compared between unstimulated HeLa cells and 4 h EGF-treated HeLa cells using fixed laser power and detector voltages. 
(D) Quantification of GalNac-T1 and HPL enrichment at the Golgi in HeLa cells treated with EGF for indicated times. 30 cells were quantified for each 
sample. Error bars show SEM. Statistical significance (p) measured by two-tailed paired t test. * and **, P < 0.001 relative to mean HPL or GalNac-T1 
staining, respectively, in unstimulated cells (0 h). This is a representative example from three independent experiments. In all images nuclei were stained 
using Hoechst and colored blue. Bar, 10 µm.847 Src regulates protein O-glycosylation • Gill et al.
enable its delivery and retention in the ER. Muc-PTS targeting 
to the ER and not the Golgi was verified under both active and 
inactive Src-expressing conditions by costaining with the ER 
and Golgi markers PDI and Giantin, respectively (Fig. 5, B–E). 
Muc-PTS glycosylation status could be evaluated either by a 
size shift on gel after immunoprecipitation (due to both the added 
molecular weight of GalNAc residues and reduced binding to 
SDS; Fukuda and Tsuboi, 1999) or by its binding to HPL aga-
rose beads. To verify that Muc-PTS glycosylation in the ER could 
be detected, a constitutively ER-targeted form of GalNac-T2 
(abbreviated ER-GALNT2) was constructed by fusing GalNac-T2 
to the cytosolic tail of the ER resident MHC class II protein p33 
(Röttger et al., 1998). As a control, ER-GALNT2 containing the 
H226D mutation, which completely abrogates its catalytic ac-
tivity (Fritz et al., 2004), was also generated. After coexpression 
with active ER-GALNT2 in HEK293T cells, the apparent molecu-
lar size of Muc-PTS was higher (45–55 kD) than when expressed 
(Fig. 4 A), after EGF treatment it colocalizes with ERGIC53 
in punctate structures distributed throughout the cell (Fig. 4 B). 
Similarly, anti-Tn staining colocalizes with ERGIC53-positive 
punctate structures only in EGF-stimulated HeLa cells (not 
depicted). Due to weak antibody staining, visualization of 
GalNac-Ts in the ER is arduous but HPL and anti-Tn staining 
can both be found colocalizing with the ER protein markers 
PDI (protein disulphide isomerase) and calreticulin, respectively 
(Fig. 4, C and D; and unpublished data). These results indicate 
that GalNac-Ts are being relocalized to the ER and the ERGIC 
under conditions of Src activation.
To probe for GalNac-Ts in the ER, an ER-trapped reporter 
for GalNac-T activity (Muc-PTS) containing a proline, threonine, 
and serine (PTS)–rich sequence from the Muc5AC mucin was 
constructed (Fig. 5 A). This reporter contains up to 15 sites of 
GalNAc addition, as well as a secretion signal sequence fused 
to GFP at its N terminus and a KDEL motif at its C terminus to 
Figure 3.  Redistribution of GalNac-Ts from the Golgi is dependent on Src activity levels. (A) HPL staining redistributed out of the Golgi (Giantin) in HeLa 
cells upon EGF stimulation (100 ng/ml) for 4 h is inhibited with cotreatment of 10 µM Src kinase inhibitors SKI and SU6656. (B) Quantification of HPL 
enrichment at the Golgi in HeLa cells cotreated with EGF and either DMSO or 10 µM Src inhibitors (SKI, SU6656) for indicated times. 30 cells were quantified for 
each sample. Error bars show SEM. Statistical significance (p) measured by two-tailed paired t test. * or **, P < 0.001 or P < 0.05, respectively, relative 
to mean HPL staining in DMSO-treated cells at each time point. This is a representative example from two independent experiments. (C) Quantification of 
HPL enrichment at the Golgi in HeLa cells cotreated with PDGF (50 ng/ml) and either DMSO or 10 µM SKI for indicated times. 30 cells were quantified for 
each sample. Error bars show SEM. Statistical significance (p) measured by two-tailed paired t test. *, P < 0.001 relative to mean HPL staining in DMSO-treated 
cells at each time point. This is a representative example from two independent experiments. (D) Low resolution immunofluorescence studies of HPL stain-
ing highlighting a reticulated network only in Src-activated SYFsrc fibroblasts and not Src-deficient SYF fibroblasts. (E) High resolution immunofluorescence 
studies of HPL and Mannosidase II staining in Src-deficient SYF and Src-activated SYFsrc fibroblasts. In all images nuclei were stained using Hoechst and 
colored blue. Bars: (A and E) 10 µm; (D) 50 µm.JCB • VOLUME 189 • NUMBER 5 • 2010   848
Golgi enzymes have been shown to be enriched in COP-I vesi-
cles in some conditions (Lanoix et al., 2001; Malsam et al., 2005). 
Our previous work indicated that Src regulates COP-I vesicular 
traffic (Bard et al., 2003). Together, this suggests that GalNac-T re-
distribution to the ER upon Src activation could be mediated by 
COP-I vesicles. Consistently, upon EGF activation, the distribution 
of two coat components, 1 and 1, were redistributed from the 
Golgi apparatus to punctate structures distributed throughout the 
cell and reminiscent of the ERGIC (Fig. 6, A and B). Before EGF 
stimulation, GalNac-T1 colocalizes exclusively with 1 and 1 
COP-I coat components at HPL-stained Golgi membranes (Fig. 6, 
C and E). By contrast, after EGF stimulation GalNac-Ts also co-
localize partially with 1 and 1 COP-I coat components in the 
new punctate structures (Fig. 6, D and F). These data suggest 
that GalNAc-Ts are being redistributed from the Golgi apparatus 
to the ER by a process that requires COP-I vesicles.
Arf1 activity is required for  
GalNac-T redistribution
Arf proteins are well-characterized regulators of COP-I vesicle 
biogenesis (for review see D’Souza-Schorey and Chavrier, 2006). 
Preliminary experiments indicated that expression of active 
Src(E378G) in Src-deficient SYF cells reduces Arf1 levels on 
Golgi membranes (unpublished data). Exogenously expressed 
Arf1-GFP at the Golgi in serum-starved HeLa cells was re-
distributed to punctate cytoplasmic structures after EGF stimu-
lation (Fig. 7, A and B). To test Arf1 function in GalNac-T 
redistribution, we used the constitutively active mutant Arf1(Q71L), 
which blocks the final stages of COP-I vesicle biogenesis at the 
Golgi due to its inability to hydrolyze bound GTP into GDP 
(Dascher and Balch, 1994). Expression of wild-type Arf1-GFP 
and Arf1(Q71L)-GFP alone does not perturb GalNac-T loca-
tion in unstimulated HeLa cells, as indicated by HPL staining 
concentrated at the Golgi (Fig. 7 A). After EGF stimulation for 
4 h, HPL staining in wild-type Arf1-GFP–expressing HeLa cells 
was dispersed in a fashion similar to untransfected cells (Fig. 7 B). 
By contrast, Arf1(Q71L)-GFP–expressing HeLa cells displayed 
less HPL dispersion with a significant amount remaining co-
localized with Giantin-stained Golgi membranes (Fig. 7 B). 
Quantification of HPL Golgi staining during EGF stimulation 
revealed a slower rate of decrease with Arf1(Q71L)-GFP at all 
times (Fig. 7 C). Arf1(Q71L)-GFP also blocked HPL redistri-
bution under expression of active Src(E378G)-DsRed (SrcE-
DsRed) in Src-deficient SYF fibroblasts (Fig. 7, D and E). 
Interestingly, when Arf1 function is inhibited, active Src accu-
mulates more readily at the Golgi (Fig. 7 E). As a control for 
these studies, we found that coexpression of inactive Src (SrcK-
DsRed) with wild-type Arf1 does not promote redistribution of 
GalNac-Ts, indicated by HPL staining enriched at the Golgi 
(Fig. 7 F). Altogether, these results show that Arf(Q71L) but not 
wild-type Arf1 can block or delay the trafficking of GalNAc-Ts 
to the ER induced by Src. To directly test the effect of Arf(Q71L) 
on the redistribution of GalNAc-Ts, we used the ER-trapped 
Muc-PTS glycosylation reporter. As judged by the smaller ap-
parent size and less efficient pull-down using HPL, the extent 
of Muc-PTS GalNAc glycosylation was much lower in cells 
where Arf1(Q71L) but not wild-type Arf1 was coexpressed with 
alone or with inactive ER-GALNT2(H226D) (45 kD; Fig. 5 F). 
In addition, a significant increase of Muc-PTS binding to HPL 
resin was observed when Muc-PTS was coexpressed with active 
ER-GALNT2, demonstrating that it is significantly glycosylated 
only when active GalNac-Ts are present in the ER.
Muc-PTS was next used to monitor the apparition of endog-
enous GalNac-T activity in the ER upon Src activation. Muc-PTS 
was transfected into HEK293T cells 36 h before overnight serum 
starvation and subsequent EGF stimulation to activate Src. After 
2–4 h of EGF stimulation, the extent of GalNAc modification in 
Muc-PTS was substantially higher as judged by increased bind-
ing to HPL agarose (Fig. 5 G). Similarly, only active Src and not 
inactive Src could promote GalNac-T activity in the ER when 
Muc-PTS was cotransfected with Src expression plasmids as 
seen by both anti-FLAG immunoprecipitation and HPL pull-down 
(Fig. 5 H). In the active Src-expressing conditions, a significant 
fraction of Muc-PTS had a shifted apparent molecular size (up to 
55 kD) similar to the shift observed with ER-targeted GalNac-T2 
(Fig. 5, F and H). This is consistent with our immunofluorescence 
results indicating more extensive GalNac-T redistribution upon 
expression of an active Src than upon EGF stimulation.
Src activation induces COP-I  
staining redistribution
Golgi-to-ER retrograde traffic of several proteins such as the 
KDEL-R has been shown to depend upon COP-I vesicles. The 
COP-I coat is built from several subunits and is thought to provide 
a force to sort cargo into transport intermediates (Hsu et al., 2009). 
Table I. Effect of Src activation on redistribution of Golgi resident proteins
Golgi proteins  
tested
Redistributed to ER 
under EGF stimulation 
(HeLa cells)
Redistributed to ER  
under Src microinjection 
(either mouse SYF or  
human WI38 fibroblasts)
Structural proteins
Giantin  NT
Glycosyltransferases
Mannosidase II   (SYF)
Mannosidase IC
a NT  (SYF)
4-GALT
b NT  (SYF)
C2GnT
c NT  (SYF)
GalNac-T1 ++ ++ (WI38)
GalNac-T2 ++ ++ (WI38)
GalNac-T3 ++ ++ (WI38)
GalNac-T4 NT ++ (WI38)
GalNac-T6 NT ++ (WI38)
COP-I regulatory 
proteins
Arf1
d ++ ++ (SYF)
COP-I 1 ++ ++ (SYF)
COP-I 1 ++ NT
, not affected; ++, strong redistribution; NT, not tested.
aTransfection of full-length Mannosidase IC tagged at its N terminus with an 
HA tag.
bTransfection of 4-GALT GFP-tagged reporter construct.
cTransfection of full-length C2GnT tagged at its C terminus with a DsRed tag.
dTransfection  of  full-length  Arf1  tagged  at  its  C  terminus  with  a  GFP  or  a   
V5 tag.849 Src regulates protein O-glycosylation • Gill et al.
HPL staining in HeLa cells treated for 3 h with EGF and PDGF, 
respectively, relative to unstimulated serum-starved cells (Fig. 8 B). 
To independently verify this increase of O-glycosylation initia-
tion, we metabolically labeled cells with GalNAz, a GalNAc   
analogue that can be incorporated into proteins by GalNac-Ts 
and, after cell lysis, specifically labeled with a FLAG epitope 
(Laughlin and Bertozzi, 2007). When SYF and SYFsrc cells are 
GalNAz labeled for 24 h and similar amounts of total cell lysate 
are analyzed using anti-FLAG Western blot, SYFsrc cells dis-
play significantly higher GalNAz labeling of various proteins 
(Fig. 8 C). Similarly, EGF stimulation of serum-starved HeLa 
cells results in higher GalNAz incorporation after 2 h and more 
significantly after 4 h (Fig. 8 D). The Western blot patterns indi-
cate that multiple proteins have an increased incorporation of 
GalNAz, suggesting that the propensity of various residues in 
various proteins to become O-glycosylated increases significantly 
active Src (SrcE; Fig. 7 G). Overall, these results demonstrate 
that Arf1 is critical for mediating trafficking of GalNAc-Ts to 
the ER upon Src activation. Together with our results on COP-I 
staining, this strongly suggests that GalNAc-Ts are redistributed 
from the Golgi to the ER by COP-I vesicles.
O-glycosylation initiation is up-regulated 
upon Src activation
We hypothesized that redistribution of GalNac-Ts from the Golgi 
to the ER could significantly increase total O-glycosylation ini-
tiation by exposing protein substrates to GalNac-Ts earlier and 
for a longer time. Consistent with this idea, total cellular HPL 
staining intensity increases 2.1-fold between Src-deficient SYF 
cells and activated Src SYFsrc cells, and 2.5-fold between basal 
Src NIH3T3 cells and activated Src NIH3T3-vsrc cells (Fig. 8 A). 
In addition, we also observed a 2- and 1.8-fold increase in total 
Figure 4.  GalNac-Ts are trafficked to ERGIC and ER compartments upon Src activation. (A) GalNac-T1 and ERGIC53 staining colocalizes moderately only 
at the Golgi apparatus (Giantin) in unstimulated HeLa cells. (B) GalNac-T1 and ERGIC53 staining colocalizes in novel punctate ER-to-Golgi intermediate 
compartment (ERGIC) structures upon EGF treatment (100 ng/ml) for 4 h. These structures stain positively for HPL. (C) HPL staining is present exclusively at the 
Golgi with no significant colocalization with ER marker (PDI) in unstimulated HeLa cells. (D) HPL staining is present in diffuse structures that stained with an 
ER marker (PDI) upon EGF treatment for 4 h. In all images nuclei were stained using Hoechst and colored blue. Bar, 10 µm.JCB • VOLUME 189 • NUMBER 5 • 2010   850
Müller, 2000). To test whether the density of GalNAc modifica-
tion in such a typical O-glycosylation cluster could be increased 
by GalNac-T relocation, we used a secreted reporter derived from 
Muc1, the Muc1-TR6 reporter (Fig. 8 E). This construct was 
previously reported by Müller and Hanisch (2002), with the dif-
ference that a Myc tag present in the original construct has been 
upon GalNac-T relocation to the ER. O-glycosylation is known 
to often occur on clusters of multiple Ser or Thr residues (Fukuda 
and Tsuboi, 1999; Hanisch and Müller, 2000; Tarp and Clausen, 
2008). For example, the prototypical MUC1 protein contains a 
variable number of 20 amino acid tandem repeat sequences that 
each contain 5 putative sites for GalNAc addition (Hanisch and 
Figure  5.  An  ER-trapped  GalNac-T  activity  reporter 
demonstrates that GalNac-Ts are active in the ER upon   
Src-induced  redistribution.  (A)  Schematic  of  Muc-PTS 
GalNac-T  activity  reporter.  (B  and  C)  Immunofluores-
cence studies of Muc-PTS cotransfected in HeLa cells with 
inactive Src (SrcK-mCherry, containing K295M mutation) 
and staining with ER (PDI) (B) or Golgi (Giantin) (C) markers.   
(D  and  E)  Immunofluorescence  studies  of  Muc-PTS   
cotransfected in HeLa cells with active Src (SrcE-mCherry, 
containing  E378G  mutation)  and  staining  with  ER  (D) 
or Golgi (E) markers. (F) SDS-PAGE analysis of Muc-PTS 
expressed alone in HEK293T cells or cotransfected with 
active  (ER-GALNT2)  or  inactive  (ER-GALNT2(H226D))   
ER-targeted  GalNac-T2.  Muc-PTS  was  either  immuno-
precipitated with an anti-FLAG antibody or pulled down 
using HPL-conjugated agarose. (G) SDS-PAGE analysis of   
Muc-PTS  pulled  down  using  HPL-conjugated  agarose   
after expression in HEK293T cells and treatment with EGF 
(100 ng/ml) for indicated times. (H) SDS-PAGE analysis 
of Muc-PTS coexpressed in HEK293T cells with either in-
active Src (SrcK) or active SrcE (SrcE). Muc-PTS was either 
immunoprecipitated with an anti-FLAG antibody or pulled 
down using HPL-conjugated agarose. In all images nuclei 
were stained using Hoechst and colored blue. Bar, 10 µm.851 Src regulates protein O-glycosylation • Gill et al.
Figure 6.  Upon EGF stimulation, COP-I 1 and 1 subunits are redistributed from the Golgi into punctate structures that also contain GalNac-T1.  
(A and B) COP-I 1 (A) and 1 (B) staining at the Golgi (Giantin) in unstimulated HeLa cells (left panels) become redistributed out of the Golgi after EGF 
treatment (100 ng/ml) for 4 h (right panels). The increase in number and intensity of punctate cytoplasmic COP-I–stained structures suggests that the rate 
of COP-I trafficking is significantly increased. (C–F) GalNac-T1 staining colocalizes with the 1 (C) or 1 (E) COP-I subunit exclusively at the Golgi (HPL) 
in unstimulated HeLa cells, but also in dispersed punctate structures that stain positive for 1 (D) or 1 (F) COP-I after EGF treatment for 4 h. In all images 
nuclei were stained using Hoechst and colored blue. Bar, 10 µm.
replaced here with a V5 tag. The reporter contains six Muc1 tan-
dem repeats each with five putative sites for GalNAc addi-
tion and was found to display glycosylation densities similar to 
endogenous Muc1 (Müller and Hanisch, 2002). The Muc1-TR6 
reporter was cotransfected with either active Src (SrcY, contain-
ing the activating point mutation Y527F) or inactive Src (SrcK) JCB • VOLUME 189 • NUMBER 5 • 2010   852
Figure 7.  A dominant-negative Arf(Q71L) mutant prevents redistribution of GalNac-Ts induced by Src activation. (A) Wild-type Arf1-GFP (Arf1(WT)-GFP) 
and mutant Arf1(Q71L)-GFP colocalize primarily at the Golgi (Giantin) in unstimulated HeLa cells. (B) Expression of mutant Arf1(Q71L)-GFP (right panels) 
but not Arf1(WT)-GFP (left panels) resists redistribution of GalNac-Ts (indicated by HPL staining) from the Golgi to the ER under EGF treatment (100 ng/ml) 
for 4 h. The amount of Arf1(WT)-GFP (left panels) but not Arf1(Q71L)-GFP (right panels) at the Golgi is significantly decreased after EGF stimulation.   
(C) Quantification of HPL enrichment at the Golgi in HeLa cells expressing either Arf1(WT)-GFP or mutant Arf1(Q71L)-GFP after EGF treatment for indicated 
times. 30 cells were quantified for each sample. Error bars show SEM. Statistical significance (p) measured by two-tailed t test. * and **, P < 0.05 or P < 0.001, 
respectively, relative to mean HPL staining in cells expressing Arf1(WT)-GFP at each time point. This is a representative example from two independent 
experiments. (D and E) Expression of mutant Arf1(Q71L)-GFP (D) but not Arf1(WT)-GFP (E) blocks redistribution of GalNac-Ts (indicated by HPL staining) 
under cotransfection with active Src (SrcE-DsRed) in Src-deficient SYF fibroblasts. Active Src is enriched at the Golgi only upon expression of Arf1(Q71L)-GFP   853 Src regulates protein O-glycosylation • Gill et al.
Src activation at the Golgi induces GalNac-T 
redistribution to the ER
GalNac-T redistribution to the ER is clear from HPL or anti-Tn 
antibody staining studies and from use of the ER glycosyl-
ation reporter. GalNac-Ts also localize in vesicular structures 
that costain with ERGIC-53 and HPL. This suggests under 
conditions of high Src activity, GalNac-Ts continuously cycle 
between the ER and the Golgi while their efficient recycling to 
the ER results in a shift in steady-state distribution. Src could 
also affect the intra-Golgi distribution of GalNac-Ts, which 
were shown to be present in several cisternae in HeLa cells 
(Röttger et al., 1998). But our current microscopic resolution 
is not sufficient to assess this. The ER redistribution occured 
with all the members of the GalNac-T family tested. By com-
parison, Golgi peripheral proteins (Giantin) and glycosylation 
enzymes (Mannosidase II and  1,4-galactosyltransferase) are 
not redistributed after Src activation, suggesting that GalNac-Ts 
contain a feature enabling specific sorting. As the cytosolic 
tails of GalNac-Ts do not contain conserved tyrosines, direct 
phosphorylation by Src is excluded. How the GalNac-Ts are 
specifically  sorted  is  therefore  a  particularly  exciting  chal-
lenge for the future.
Src mediates GalNac-T redistribution  
to the ER by COP-I vesicles
EGF stimulation and Src activation affect the intracellular dis-
tribution of the small GTPase Arf1 and the COP-I coat, both 
reducing their levels at the Golgi and generating punctate cyto-
plasmic structures. Some of these structures stain positive   
for GalNac-Ts, suggesting that GalNac-Ts are trafficked by 
COP-I–coated intermediates. Consistently, a dominant-negative 
form of Arf1, Arf1(Q71L), blocks redistribution of GalNac-Ts 
from the Golgi to the ER under conditions of Src activation. 
Interestingly, under Arf1(Q71L) expression, active Src is read-
ily detected at the Golgi, which is usually difficult to visual-
ize. By comparison, inactive Src accumulates readily at the 
Golgi  (Fig.  7,  E  and  F). A  possible  interpretation  is  that 
membrane-bound Src is incorporated in the GalNac-T trans-
port intermediates that it induces. This would explain why active 
Src is not easily detected at the Golgi. Src vesicular traffick-
ing will be interesting to explore in the future. Interestingly, 
our data suggest that COP-I–coated structures formed upon Src 
activation are enriched in GalNac-Ts but not other glycosyl-
transferases. Instances of COP-I vesicles with specific content 
have been previously reported (Lanoix et al., 2001; Malsam 
et al., 2005). Our results point to a way to induce and control 
the  formation  of  a  subset  of  COP-I  vesicles,  which  may 
greatly facilitate investigation of the mechanistic basis of COP-I 
cargo specificity.
in HEK293T cells before harvesting of the culture medium, pu-
rification of Muc1-TR6 using either Ni-NTA (binds His6 tag) or 
HPL-conjugated agarose before GalNAz labeling with the Flag 
tag. Muc1-TR6 coexpressed with active Src contains a signifi-
cantly higher density of GalNAc as judged by increased anti-
FLAG staining for a similar amount of Muc1-TR6 relative to 
coexpression with inactive Src (Fig. 8 F). Therefore, these results 
indicate that Src activation can increase the density of GalNAc 
addition on secreted O-glycosylated proteins, presumably through 
redistribution of GalNac-Ts to the ER.
Discussion
Growth factor–induced Src signaling at  
the Golgi
Growth factor receptor engagement induces a vast array of re-
sponses that are often mediated by a cascade of kinase activa-
tion. In recent years it has emerged that the Golgi apparatus is 
regulated by kinases both during mitosis (for review see Colanzi 
and Corda, 2007) and interphase, for example by PKD (Van Lint   
et al., 2002), YSK1 (Preisinger et al., 2004), ERK (Bisel et al., 
2008), and others (Preisinger and Barr, 2005). The signaling 
cascade consisting of heterotrimeric G protein subunits -gamma 
(Jamora et al., 1999), PKD (Liljedahl et al., 2001; Bossard et al., 
2007) and PKCeta (Díaz Añel and Malhotra, 2005) function to 
regulate TGN-to-plasma membrane traffic (Bard and Malhotra, 
2006). YSK1 and ERK are proposed to regulate Golgi reorien-
tation during cell migration through phosphorylation of GM130 
and GRASP65, respectively (Preisinger et al., 2004; Bisel et al., 
2008). Signaling initiated at the plasma membrane has been shown 
to be relayed to the Golgi apparatus, notably for small GTPases 
H-Ras and N-Ras (Quatela and Philips, 2006; Fehrenbacher et al., 
2009). In these studies and others, activated Src was reported to 
be present on Golgi membranes (Bard et al., 2002; Chiu et al., 
2002). The mechanisms underlying signal translocation from 
the plasma membrane to the Golgi remain unclear. Activated 
Ras appears to translocate to the Golgi by cytosolic diffusion 
(Goodwin et al., 2005). For Src, it is possible that membrane-
anchored signaling complexes traffic from the endosomes to the 
Golgi (Roskoski, 2004). In addition to growth factor stimula-
tion, Src can be activated through mutations (v-Src) or higher 
expression levels (SYFsrc cell line and multiple human cancers 
and derived cell lines; Ottenhoff-Kalff et al., 1992). Our results 
show that Src activation by growth factor stimulation or increased 
expression affects GalNac-T intracellular distribution in a similar 
way. Recently, it was reported that Src could be activated at the 
Golgi level by an increase in cargo load through the KDEL-R 
(Pulvirenti et al., 2008). It will be interesting to test in the future 
whether this mode of activation affects GalNac-T localization.
(E) and not Arf1(WT)-GFP (D). (F) Co-expression of Arf1(WT)-GFP and inactive Src (SrcK-DsRed) in Src-deficient SYF fibroblasts does not induce trafficking of 
GalNac-Ts from the Golgi (indicated by normal HPL staining). In addition, inactive Src is highly enriched at the Golgi. (G) SDS-PAGE analysis of ER-trapped 
Muc-PTS GalNac-T activity reporter coexpressed in HEK293T cells with either inactive Src (SrcK) or active Src (SrcE) and Arf1(WT) or Arf1(Q71L). Muc-PTS 
was either immunoprecipitated with an anti-FLAG antibody or pulled down using HPL-conjugated agarose. In all images nuclei were stained using Hoechst 
and colored blue. Bars: (A–C) 10 µm; (D–F) 20 µm.
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Figure 8.  Src activity increases O-glycosylation initiation efficiency. (A) Quantification of total cellular HPL staining in model Src fibroblasts using a high 
throughput confocal microscope. At least 200 cells per well and three wells per cell line were quantified. Error bars show SEM. Statistical significance (p)   
was measured using a two-tailed paired t test. * and **, P < 0.001 relative to the mean HPL intensity in SYF and NIH3T3-WT cells, respectively. Nor-
malization of SYFsrc and NIH3T3-vsrc HPL intensities was performed relative to SYF and NIH3T3-WT cell mean HPL intensities, respectively. This is a 
representative example from two independent experiments. (B) Quantification of total cellular HPL staining in HeLa cells treated with EGF (100 ng/ml) 
or PDGF (50 ng/ml) for indicated times using a high throughput confocal microscope. At least 200 cells per well and three wells per sample were 
quantified. Error bars show SEM. Statistical significance (p) was measured using a two-tailed paired t test. * and **, P < 0.001 relative to the mean 
HPL intensity in untreated cells for EGF and PDGF samples, respectively. This is a representative example from two independent experiments. (C) SDS-
PAGE analysis of SYF and SYFsrc cell lysate metabolically labeled using GalNAz-FLAG. (D) SDS-PAGE analysis of unstimulated and EGF-treated HeLa 
cells metabolically labeled using GalNAz-FLAG for the indicated times. (E) Schematic of the Muc1-TR6 secreted O-glycosylation reporter. (F) SDS-PAGE 
analysis of secreted Muc1-TR6 purified using either agarose-conjugated Ni-NTA or HPL before labeling with GalNAz-FLAG. (G) A model for Src-induced 
Golgi-to-ER retrograde trafficking of GalNac-T enzymes. Under normal cellular conditions, GalNac-Ts are predominantly localized to the cis-face of the 
Golgi apparatus and initiation of O-glycosylation occurs in the Golgi apparatus. Upon activation of Src, GalNac-Ts are selectively trafficked to the ER. 
This increases the efficiency of O-glycosylation initiation and results in a greater density of GalNAc added onto mucin-like proteins (further O-glycan 
modifications are not included for sake of clarity).855 Src regulates protein O-glycosylation • Gill et al.
proteins. It could affect the folding and activity of secreted pro-
teins or affect their sensitivity to proteases. Indeed, glycosyl-
ation often protects glycoproteins from proteolytic degradation. 
For example, O-GalNAc glycosylation competes with trans-
Golgi proprotein convertase cleavage of the FGF23 secreted 
factor (Kato et al., 2006). One interesting possibility is that the 
increase in O-glycan chain density could affect the type of 
O-glycans synthesized. Recently, high-density GalNAc modifica-
tion was shown to inhibit the core forming enzymes that ex-
tend the glycan chain (Brockhausen et al., 2009). GalNac-T 
relocation induced by Src could therefore favor shorter glycan 
chain lengths. Interestingly, it has long been observed that can-
cerous transformation is often associated with an increase in 
short O-glycans such as the Tn, sialylated Tn, and T antigens 
(Brockhausen, 2006). These changes in glycans types could in 
turn affect binding of lectin molecules. O-glycan–specific lec-
tins such as the selectins have indeed been shown to be essen-
tial  for  lymphocyte  adhesion  (Tian  and Ten  Hagen,  2009). 
Regulation of cell adhesion by O-glycans has been shown   
in vitro for cancer cell lines (Clément et al., 2004; Julien et al., 
2005, 2006) and genetically in the Drosophila wing where de-
letion of pgant3, a GalNac-T, leads to loss of adhesion between 
epithelial sheets and blisters (Zhang et al., 2008). Perturbation 
of cell adhesion could facilitate cell migration and metastasis 
in vivo, perhaps explaining the poor prognosis of cancer patients 
found to have short O-glycans (Itzkowitz et al., 1990; Nakamori 
et al., 1993; Ogata et al., 1998). Interestingly, Src regulates both 
cell adhesion and cell migration and has been associated with 
metastasis in vivo (Yeatman, 2004). Therefore, it is tempting to 
speculate that regulation of O-glycosylation by GalNac-T redis-
tribution plays a significant role in Src-mediated regulation of 
cell adhesion and migration in vitro and metastasis in vivo.
Materials and methods
Cloning
Plasmids encoding full-length wild-type chicken SRC and an E378G-
containing point mutant were a gift from Roland Baron (Harvard Medical 
School, Boston, MA). A plasmid encoding full-length HA-tagged Mannosi-
dase I-C was a gift from Annette Hercovics (McGill Cancer Center, Montreal, 
Canada). A plasmid encoding full-length C2GnT was a gift from Minoru 
Fukuda (Burnham Institute, San Diego, CA). Full-length SRC was amplified 
by PCR using attB-containing primers and cloned into pDONR221 using 
BP-clonase II (Invitrogen). Human GALNT2 (GenBank/EMBL/DDBJ acces-
sion no. NM_004481), ARF1 (NM_001024227), and a short sequence 
(7746–8033) from the human MUC5AC gene (XM_001130382) were 
PCR amplified and cloned into pDONR221 from cDNA synthesized using 
SuperScript-III (Invitrogen) and total RNA extracted from HT29-18N2 cells. 
Addition of the FLAG(DYKDDDDK)-KDEL sequence to the Muc5AC entry 
clone was achieved by PCR using a primer extension method before re-
amplification using attB-containing primers and cloning into pDONR221. 
Replacement of the N terminus (residues 1–5) of GALNT2 with the N ter-
minus (residues 1–46) of MHC class II light chain invariant protein p33 
(NM_001025159) was achieved by PCR using attB-containing primers be-
fore cloning into pDONR221. The Muc1-TR6 O-glycosylation reporter was 
constructed by PCR before reamplification using attB-containing primers 
and  cloning  into  pDONR221.  All  point  mutants  were  introduced  into 
GALNT2-, ARF1-, and SRC-containing pDONR221 entry clones by PCR 
using overlapping mutagenic primers and KOD polymerase (Merck).   
Human Muc5AC-PTS-KDEL was subcloned into pFB-ssHGH-NemGFP-DEST 
(N-terminal ER signal sequence from human growth hormone fused to 
emGFP). SRC and GALNT2 were subcloned into pFB-CDsRed-DEST and 
pFB-CmCherry-DEST (C-terminal DsRed or mCherry tags). C2GnT was 
subcloned into pDsRed-Monomer-Hyg-N1 (Takara Bio Inc.) using NheI/BamHI 
Src activation up-regulates  
O-GalNAc glycosylation through  
GalNac-T redistribution
Constitutive high Src activity and activation of Src after growth 
factor stimulation results in higher total cell intensity labeling 
with HPL, suggesting more GalNAc is incorporated into proteins. 
Consistently, GalNaz metabolic labeling reveals several proteins 
with de novo or enhanced GalNAc incorporation, indicating 
that normally unmodified Ser or Thr residues are becoming 
O-glycosylated upon Src activation. This is observed at the whole-
cell level and could concern ER-localized proteins. However, 
the secreted reporter Muc1-TR6 purified from cell supernatant 
also has enhanced glycosylation, indicating that the O-GalNAc 
increase affects secreted and cell surface proteins. The de novo 
addition of GalNAc could occur on Ser or Thr residues hidden 
after full protein folding but exposed in the ER. Alternatively, 
de novo glycosylation could also occur in “hot-spots” partially 
glycosylated when GalNac-Ts are restricted to the Golgi. This 
is clearly occurring with the Muc1-TR6 secreted reporter, which 
contains 30 possible sites (6 tandem repeats each with 5 possible 
sites). High-density glycan attachment is a hallmark of numerous 
O-GalNAc glycosylated proteins. Muc1, for example, contains a 
polymorphic central region of up to 120 tandem repeats, resulting 
in a potential number of 600 O-glycans per central region (Hanisch 
and Müller, 2000). The density of O-glycan chains on Muc1 
tandem repeats is variable. For example, Muc1 from lactating 
breast or from cancer cell lines contains an average of 2.6 and 
4.8 glycans per repeat, respectively (Müller et al., 1997, 1999; 
Müller and Hanisch, 2002). O-glycan density can also vary de-
pending on cell activation status (Wu et al., 2009).
These variations have usually been attributed to changes 
in glycosyltransferase expression patterns, but our study sug-
gests that intracellular distribution could be an important factor. 
How exactly redistribution favors higher density is not clear at 
this stage. It might simply allow more time for the GalNac-Ts 
to modify their protein substrates. Alternatively, redistribution 
of GalNac-Ts to an earlier compartment could lower their compe-
tition with other enzymes. Indeed, GalNac-Ts are sensitive to 
neighboring site glycosylation status (Gerken et al., 2002, 2004) 
and require their lectin domain for high density O-GalNAc gly-
cosylation (Wandall et al., 2007). The lectin domain binds   
-linked GalNAc residues and will therefore be affected by 
the core forming enzymes which modify the GalNac residue.
Potential physiological significance of  
O-GalNAc glycosylation regulation
O-GalNAc glycans have been implicated in multiple and di-
verse physiological functions (for reviews see Hang and Bertozzi, 
2005; Brockhausen, 2006; Tarp and Clausen, 2008; Tian and 
Ten Hagen, 2009). Consistently, the extent and specific types 
of O-glycans are known to vary extensively between tissues 
(Brockhausen, 2006) and during development (Laughlin et al., 
2008; Laughlin and Bertozzi, 2009). Recently, genetic dele-
tions in mice and Drosophila have revealed essential roles for 
GalNac-Ts and enzymes acting downstream (Tian and Ten Hagen, 
2009). Redistribution of GalNac-Ts to the ER could affect cell 
physiology in multiple ways, for example, by altering ER resident JCB • VOLUME 189 • NUMBER 5 • 2010   856
and cytoplasm regions were determined using the intensity of the Golgi 
marker (GM130 or Giantin) staining (Fig. 1 C). The ratio of average inten-
sity at the Golgi (along the line) over intensity average in the cytoplasm 
was then calculated. The ratio was averaged for 30 cells and the SEM was 
calculated. Statistical significance was measured using a paired t test as-
suming a two-tailed Gaussian distribution.
O-glycosylation reporter analysis
HEK293T cells were transfected using a calcium phosphate method. In 
brief, 1-ml transfection complexes composed of 10–30 µg of DNA diluted in 
250 mM calcium phosphate and mixed with BBS buffer (140 mM sodium 
chloride, 0.7 mM disodium hydrogen phosphate, and 25 mM N,N-Bis(2-
hydroxyethyl)-2-aminoethanesulfonic acid [BES], pH 6.95 [20°C]) by vor-
tex were incubated at room temperature for 15 min before addition to 
cells. HEK293T cells were seeded 8–24 h before addition of transfection 
complex to obtain an optimal confluency (80–90%) for transfection. The 
next day, the growth medium was replaced and the cells were further incu-
bated for 24–48 h. Metabolic labeling of HEK293T cells with 20 µM GalNAz 
was performed 24 h before transfection with Muc1(TR6) O-glycosylation re-
porter. Cells were further incubated for 30 h before replacement of the me-
dium with low serum opti-MEM (Invitrogen), which was harvested after an 
additional 24 h. Cells were washed twice using ice-cold D-PBS before 
scraping in D-PBS. Cells were centrifuged at 300 g for 5 min at 4°C and 
the cell pellet snap-frozen in liquid N2. All cell pellets were stored at 80°C 
until use. Cells were thawed on ice in the presence of ice-cold immunopre-
cipitation (IP) lysis buffer (50 mM Tris [pH 8.0, 4°C], 200 mM NaCl, 0.5% 
NP-40 alternative, 1 mM DTT, and complete protease inhibitor [Roche]) for 
30 min with gradual agitation before clarification of samples by centrifuga-
tion at 10,000 g for 10 min at 4°C. DTT was omitted in all GalNAz label-
ing experiments. Clarified lysate protein concentrations were determined 
using Bradford reagent (Bio-Rad Laboratories) before sample normaliza-
tion. All subsequent steps were performed either on ice or at 4°C. IP sam-
ples were incubated with 1–2 µg of IP antibody or HPL-conjugated agarose 
(Sigma-Aldrich) overnight at 4°C. The next day, antibody-containing ly-
sates were incubated with 20 µl of washed protein G–Sepharose. IP sam-
ples were washed a total of 5 times using 1 ml of IP wash buffer (50 mM 
Tris [pH 8.0, 4°C], 100 mM NaCl, 0.5% NP-40 alternative, 1 mM DTT, 
and complete protease inhibitor [Roche]). DTT was omitted in all GalNAz 
labeling IP experiments. Samples were diluted in IP wash buffer to a final 
volume of 45 µl (including resin) before addition of 15 µl 4x SDS loading 
buffer and boiling at 95°C for 2 min. Samples were resolved by SDS-PAGE 
electrophoresis using bis-tris NuPage gels as per manufacturer’s instruc-
tions  (Invitrogen).  Samples  were  transferred  to  PVDF  membranes  and 
blocked using 3% BSA dissolved in TBST (50 mM Tris [pH 8.0, 4°C], 150 mM 
NaCl, and 0.1% Tween 20) for 2 h at room temperature or overnight at 
4°C. Membranes were washed to remove traces of BSA before incubation 
with antibodies as per manufacturer’s instructions. Membranes were washed 
five times with TBST before incubation with secondary HRP-conjugated anti-
bodies (GE Healthcare). Membranes were further washed five times with 
TBST before ECL exposure.
Microinjection
SYF and WI38 cells were seeded at desired densities in 35-mm glass-bottom 
Petri dishes (MatTek) and incubated overnight at 37°C and 10% CO2. The 
next day, media was supplemented with 20 mM Hepes (pH 7.0; 20°C) be-
fore cells were microinjected using a 0.5-µm Femtotip-loaded microinjector 
(model 5242; Eppendorf) equipped with a microscope (Axiovert 35; Carl 
Zeiss, Inc.) fitted with a heated stage. DNA constructs were diluted to 
25 ng/µl and centrifuged for 10 min at 10,000 g before microinjection 
into the cell nuclei at 90 hPa for 0.4 s. For co-microinjection, DNA con-
structs were mixed in a 1:1 molar ratio to yield a final concentration of 
25 ng/µl. Cells were incubated at 37°C and 10% CO2 for indicated times 
before either live cell imaging or fixation and staining as outlined above.
Online supplemental material
Fig. S1 shows HPL, Tn, and GalNac-T1 intracellular staining being redistrib-
uted away from the Golgi in HeLa cells treated with PDGF. Fig. S2 illustrates 
that inhibition of transcription using -Amanitin in HeLa cells during EGF 
stimulation does not affect HPL redistribution. Fig. S3 highlights that in-
tracellular HPL staining is redistributed away from the Golgi upon EGF 
or PDGF stimulation only in Src-activated SYFsrc fibroblasts and not Src-
deficient  SYF  fibroblasts.  Fig.  S4  shows  that  endogenous  GalNac-T1, 
-T4, and -T6 enzymes are redistributed away from the Golgi in WI38 
human fibroblasts microinjected with a Src expression plasmid. Fig. S5 
demonstrates that ManIC, C2GnT, and GalT glycosyltransferases as well 
as GM130 protein are not redistributed from the Golgi under increased 
restriction enzymes (C-terminal DsRed tag). ARF1 was subcloned into 
pFB-CemGFP-DEST (C-terminal emGFP tag) and pcDNA-DEST40 (C-terminal 
V5-His6 tag) (Invitrogen). Muc1-TR6 was subcloned into pcDNA-DEST40 
(no C-terminal tag added due to presence of a stop codon in the Muc1 
sequence). The pAcGFP-Golgi plasmid encoding residues 1–81 of human 
 1,4-galactosyltransferase (GalT) fused at its C terminus to GFP was also 
used (Takara Bio Inc.). All constructs were verified by sequencing before use.
Cell culture
SYF and SYFsrc mouse fibroblast cell lines were a gift from V. Malhotra 
(Centre for Genomic Regulation, Barcelona, Spain). WI38 human fibro-
blast cells, HEK293T cells, and NIH3T3 and NIH3T3-vsrc mouse fibroblast 
cells were a gift from W. Hong, V. Tergaonkar, and X. Cao, respectively 
(IMCB, Singapore). All cells were grown at 37°C in a 10% CO2 incubator. 
SYF, SYFsrc, NIH3T3, and NIH3T3-vsrc cells were grown in DME supple-
mented with 10% fetal bovine serum (FBS). HEK293T cells were grown in 
DME supplemented with 15% FBS. WI38 cells were grown in MEM supple-
mented with 10% FBS.
Immunofluorescence microscopy
Cells were seeded at desired densities onto glass coverslips in 24-well 
dishes (Thermo Fisher Scientific). After incubation at 37°C and 10% CO2 
for 8–16 h, cells were transfected using FugeneHD (Roche) as per manu-
facturer’s instructions. For growth factor stimulation experiments, cells were 
washed once using Dulbecco’s phosphate-buffered saline (D-PBS) before 
overnight serum starvation in DME (no FBS). Human recombinant EGF 
(100 ng/ml; Sigma-Aldrich) or mouse recombinant PDGF-bb (50 ng/ml; 
Invitrogen) was added along with either DMSO (no inhibitor) or 10 µM Src 
Inhibitor (SU6656 or Src kinase inhibitor I; Merck). Metabolic labeling of 
SYF and SYFsrc cells with 50 µM GalNAz (Sigma-Aldrich) was performed 
overnight in DME supplemented with 10% FBS. Metabolic labeling of serum-
starved HeLa cells with 50 µM GalNAz was performed for up to 6 h in 
DME after serum starvation overnight. All subsequent steps were performed 
at room temperature. Cells were washed for 10 min with D-PBS, fixed for 
10 min using 4% paraformaldehyde in D-PBS, washed for a further 10 min 
with D-PBS, and permeabilized with 0.2% Triton X-100 in D-PBS for 5 min. 
Cells were blocked twice for 10 min each with 2% FBS in D-PBS before 
antibody staining following the manufacturer’s instructions. Anti-GalNac-T1,   
-T2, -T3, -T4, -T6, and anti-Tn hybridomas were a gift from U. Mendel and 
H. Clausen (University of Copenhagen, Copenhagen, Denmark). Cells 
were further washed twice using 2% FBS in D-PBS and subsequently stained 
for 15–30 min with secondary Alexa Fluor–conjugated antibodies and 
Hoechst (Invitrogen). For cells stained with HPL, either Alexa 488– (Invitrogen) 
or 647–conjugated (Invitrogen) HPL was added during secondary anti-
body incubations. Cells were mounted onto glass slides using FluorSave 
(Merck) and imaged at room temperature using an inverted FluoView 
confocal microscope (model IX81; Olympus) coupled with a CCD cam-
era (model FVII) either with a 60x objective (U Plan Super Apochro-
matic [UPLSAPO]; NA 1.35) or 100x objective (UPLSAPO; NA 1.40) 
under Immersol oil. Images were acquired and processed using Olympus 
FV10-ASW software.
HPL staining quantification
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per well in a 96-well clear and flat-bottomed black imaging plate (BD) and 
incubated overnight at 37°C and 10% CO2. Alternatively, HeLa cells were 
seeded into imaging plates before serum starvation and treatment with 
EGF or PDGF as outlined above. Cells were fixed, permeabilized, and 
stained with Hoechst and Alexa 647–conjugated HPL as outlined above 
before storage in D-PBS. Cells were imaged at room temperature using a 
high throughput ImageXpress
ULTRA confocal microscope with a 40x Plan 
Fluor objective (MDS Analytical Technologies). Images were processed using 
the Transfluor HT module of the MetaXpress analysis software (MDS Ana-
lytical Technologies). In brief, a target compartment delineated by the HPL 
fluorescence was acquired (using an intensity-based cutoff) before quantifi-
cation of the integrated intensity of HPL staining within that compartment. 
Hundreds of cells were quantified and the averages as well as the SEM 
were calculated. Statistical significance was measured using a paired t test 
assuming a two-tailed Gaussian distribution. For high magnification confo-
cal images (60x objective), 60 cells were acquired per conditions. Cells 
in mitosis, with out-of-focus or highly fragmented Golgi staining, were ex-
cluded and then a total of 30 cells were chosen at random for each condi-
tion. Because HPL and GalNAc-T staining are uniformly distributed in the 
Golgi and in cytoplasm around the Golgi, the analysis of intensities along 
a line randomly drawn over the Golgi apparatus and the perinuclear cyto-
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